Investor Presentation Full Year 2017

Investor Presentation Full year 2017 Slide 29 Novo Nordisk has a strong leadership position within the growing diabetes care market Global diabetes care market by treatment class OAD Global diabetes care value market share GLP-1 Insulin Novo Nordisk AstraZeneca Sanofi Novartis Eli Lilly Takeda Merck J&J GSK 30% 27% DKK billion 500 400 Total market: CAGR¹ 15.1% Injectables: CAGR¹ 18.8% 20% 300 200 100 0 Nov 2007 CAGR¹ 33.9% CAGR¹ 17% 10% CAGR¹ 10.9% 0% Nov 2017 Nov 2007 1 CAGR for 10-year period OAD: Oral Anti-diabetic Source: IQVIA (formerly IMS) MAT Nov, 2017 value figures changing diabetes® Source: IQVIA (formerly IMS) MAT Nov, 2017 value figures Nov 2017 novo nordisk

View entire presentation